Brokerages Set Audentes Therapeutics Inc (BOLD) Target Price at $35.50

Share on StockTwits

Audentes Therapeutics Inc (NASDAQ:BOLD) has received an average recommendation of “Hold” from the fifteen brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $35.50.

Several equities analysts have weighed in on BOLD shares. HC Wainwright set a $40.00 target price on Audentes Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 8th. Mizuho upgraded Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Wednesday, August 8th. William Blair restated a “buy” rating on shares of Audentes Therapeutics in a report on Tuesday, August 7th. Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a report on Tuesday, July 10th. Finally, ValuEngine upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 1st.

In other news, Director Louis G. Lange sold 33,000 shares of the firm’s stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $40.59, for a total value of $1,339,470.00. Following the sale, the director now directly owns 386,939 shares of the company’s stock, valued at $15,705,854.01. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Mary Newman sold 8,545 shares of the firm’s stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $40.79, for a total value of $348,550.55. Following the completion of the sale, the senior vice president now directly owns 8,245 shares in the company, valued at $336,313.55. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 162,446 shares of company stock worth $6,477,534. 6.60% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of BOLD. Wells Fargo & Company MN grew its position in shares of Audentes Therapeutics by 803.8% in the first quarter. Wells Fargo & Company MN now owns 307,537 shares of the biotechnology company’s stock valued at $9,242,000 after purchasing an additional 273,511 shares during the last quarter. Rhumbline Advisers grew its position in shares of Audentes Therapeutics by 27.4% in the first quarter. Rhumbline Advisers now owns 17,008 shares of the biotechnology company’s stock valued at $511,000 after purchasing an additional 3,657 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Audentes Therapeutics in the first quarter valued at about $344,000. Swiss National Bank grew its position in shares of Audentes Therapeutics by 31.3% in the first quarter. Swiss National Bank now owns 43,600 shares of the biotechnology company’s stock valued at $1,310,000 after purchasing an additional 10,400 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Audentes Therapeutics by 31.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 45,597 shares of the biotechnology company’s stock valued at $1,371,000 after purchasing an additional 11,000 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors.

NASDAQ BOLD opened at $39.68 on Tuesday. Audentes Therapeutics has a fifty-two week low of $24.32 and a fifty-two week high of $46.18. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -11.67 and a beta of 0.77.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by ($0.07). equities research analysts anticipate that Audentes Therapeutics will post -3.33 EPS for the current year.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Recommended Story: Dividend

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.